Get the Stockscreener App
3.39
0.29%
-0.010
After Hours:
3.39
Adc Therapeutics Sa stock is traded at $3.39, with a volume of 486.24K.
It is down -0.29% in the last 24 hours and down -17.11% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.40
Open:
$3.41
24h Volume:
486.24K
Relative Volume:
0.49
Market Cap:
$431.18M
Revenue:
$79.18M
Net Income/Loss:
$-136.99M
P/E Ratio:
-3.2142
EPS:
-1.0547
Net Cash Flow:
$-120.11M
1W Performance:
+4.31%
1M Performance:
-17.11%
6M Performance:
-15.67%
1Y Performance:
+52.02%
1-Day Range:
$3.355
$3.45
1-Week Range:
$3.10
$3.45
52-Week Range:
$2.045
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.39 | 432.45M | 79.18M | -136.99M | -120.11M | -1.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus
ADC reports data from lymphoma trial, streamlines operations - MSN
ADCT News | ADC THERAPEUTICS SA (NYSE:ADCT) - ChartMill
TradingKey - TradingKey
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - Quantisnow
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation - MSN
ADC Therapeutics (ADCT) Earnings Date and Reports 2026 - MarketBeat
Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst - MarketBeat
Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report - simplywall.st
ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha
ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha
ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat
ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey
ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart
ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call - Benzinga
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics Reports Narrower Q1 2026 Loss, Beats Estimates - AlphaStreet
ADC Therapeutics Q1 2026: $0.13/share Loss Beats Estimates — Deep Dive - AlphaStreet
ADC Therapeutics (NYSE: ADCT) posts Q1 2026 loss $33M, cash $231M - Stock Titan
ADC Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
ADC Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Reports Q1 2026 Financial Results and Updates – NYSE: ADCT - Minichart
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ADC Therapeutics Q1 Earnings Call Highlights - MarketBeat
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
ADC Therapeutics : (ADCT 1Q 2026 Earnings) - marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
ADC Therapeutics SA (NYSE:ADCT) Beats Q1 Estimates, But Market Reaction Remains Subdued - ChartMill
The biopharmaceutical company ADC Therapeutics SA recently disclosed its latest financial data, showing that as of March 31, 2026, the company's cash and cash equivalents totaled 231 million USD. - Bitget
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q1 2026 Earnings - Quiver Quantitative
ADC Therapeutics reports Q1 2026: $20.0M net product revenue, $32.97M net loss - TradingView
ADC Therapeutics (NYSE: ADCT) narrows Q1 loss, sees cash runway into 2028 - Stock Titan
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates - marketscreener.com
Earnings Scheduled For May 4, 2026 - Benzinga
MSN Money - MSN
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GuruFocus
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance Singapore
ADC Therapeutics SA expected to post a loss of 21 cents a shareEarnings Preview - TradingView
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan – Company Announcement - Financial Times
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday - MarketBeat
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 - Nasdaq
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics rises on $60M PIPE financing - MSN
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adc Therapeutics Sa Stock (ADCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Apr 02 '26 |
Sale |
3.28 |
2,529,491 |
8,294,201 |
10,265,297 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
196,229 |
736,251 |
15,470,502 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
188,407 |
706,903 |
12,957,305 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
169,265 |
643,038 |
15,301,237 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
162,517 |
617,402 |
12,794,788 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):